X

Get our occasional Market Report emails

sent straight to your inbox

There’s no charge for this.

Getting latest data loading
X

Request a Call to Trade

In addition to the daily Research emails, I would also like to receive the Accendo Markets Weekly Newsletter and occasional Market Report emails highlighting various trading opportunities.
When you enter your telephone number, we may call or message you occasionally with trading opportunities. You can opt out at any time
Home / Stocks and Markets at Lows / GlaxoSmithKline (GSK.L) 11-03-20

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

GlaxoSmithKline (GSK.L) 11-03-20

Shares in GlaxoSmithKline (GSK.L) have fallen dramatically from recent highs of 1846p. Will it continue, or is this an opportunity to pick up a bargain?

 

  • This stock is one of the more significant fallers in the period.
  • Bargain hunters should be mindful of fundamentals and events, which can influence price action. Check our website and news outlets for updates.
  • Is the trend your friend, or is a bounce imminent?
  • The market often over-reacts to bad news. Traders should consider whether it is down for good reason, or is this another over-reaction?
  • Now trading at 1536.6p (at time of writing). A return to previous highs would represent a rise of 20%.
  • Shares -16% from 12-month highs; +2% from 12 month lows.

Latest News

03 Mar:  Morgan Stanley reiterates its underweight rating on GlaxoSmithKline (GSK) and reduced the target price to 1725p (from 1740p).

20 Feb:  Emma Walmsley, Chief Executive Officer, exercised 62,036 shares within the firm on the 17th February 2020. This Director currently has 779,263 shares.

20 Feb:  Emma Walmsley, Chief Executive Officer, exercised 62,036 shares within the firm on the 17th February 2020. This Director currently has 779,263 shares.

18 Feb:  Liberum Capital reiterates its hold rating on GlaxoSmithKline (GSK) and reduced the target price to 1840p (from 1930p).

13 Feb:  Societe Generale reiterates its buy rating on GlaxoSmithKline (GSK) and reduced the target price to 2240p (from 2300p).

13 Feb:  HSBC reiterates its buy rating on GlaxoSmithKline (GSK) and reduced the target price to 2050p (from 2110p).

11 Feb:  UBS reiterates its buy rating on GlaxoSmithKline (GSK) and reduced the target price to 1900p (from 1950p).

Source: Bloomberg, Reuters, Alpha Terminal, FT, DJ Newswires

 

Click to enlarge

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

About Us

Accendo Markets is an award-winning provider of CFD and spread betting trading services. We provide an execution-only service.

Get in Touch

Quick Links

Telephone calls and online chat conversations may be monitored and recorded for regulatory and training purposes.

* We provide these as underlying assets to CFDs and Spreadbets.

To view our policies and terms, please click here

This website is not intended for or directed at residents of the United States or any country outside the UK. It is not intended for use by or distribution to any person in any jurisdiction or country where its use or distribution would contravene any regulation or local law.
Prices on this page are delayed.

Like many websites, we use cookies for statistical purposes and to acquire information on general internet use. This helps ensure that you get the full benefit of our services, and enhances your browsing experience . For more details on the cookies we use, view our privacy policy under the heading 'How We Use Cookies'. By using this website, we'll assume that you're happy to receive all cookies from Accendo Markets.
Removing cookies may impede the operation of some parts of this website. For general information about cookies and how to remove them, please click here 

Accendo Markets Ltd - Highstone House, 165 High Street, Barnet EN5 5SU (UK) Telephone: 020 3051 7461 - Accendo Markets Ltd. is Authorised and Regulated by the Financial Conduct Authority (FCA) No. 475285. Accendo Markets Ltd. Registered in England and Wales No. 6417051. © Copyright Accendo Markets Ltd 2015. All rights reserved.
.